Skip to main content

Peer Review reports

From: Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

Original Submission
18 Mar 2015 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
5 Apr 2016 Editorially accepted
9 Apr 2016 Article published 10.1186/s12885-016-2301-6

You can find further information about peer review here.

Back to article page